Immunotherapy-First Bowel Cancer Trial Reports Zero Relapses After 33 Months
TL;DR
A UK-led NEOPRISM-CRC trial treated 32 patients with stage 2/3 bowel cancer using up to 9 weeks of pembrolizumab before surgery instead of post‑op chemotherapy. About 59% had no detectable cancer after treatment and surgery; after 33 months, none had a cancer relapse. The researchers highlight the potential for durable disease control with preoperative immunotherapy and are developing blood tests and immune profiling to predict responders, noting that roughly 25% relapse is expected with standard treatment after three years.
- Groundbreaking Bowel Cancer Trial Had Zero Relapses for Patients After 33 Months Good News Network
- Presurgery Pembrolizumab May Be the Future for Some Operable CRCs Inside Precision Medicine
- Bowel cancer treatment ‘halts disease for three years’ The Telegraph
- 'The cancer melted away' - Dorset man's recovery after taking part in new treatment Dorset Echo
- Trial shows durable response with preoperative immunotherapy in bowel cancer News-Medical
Want the full story? Read the original reporting
Read on Good News Network